GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Belite Bio Inc ADR BLTE · USD

Health Care · US listing · 🇺🇸 United States

Compare

157.69

+2.27%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$77.6m

FY2020FY2025

Free cash flow

−$37.2m

FY2020FY2025

Shareholders' equity

$770.5m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Gross profit—−$449,000−$399,000−$198,000−$30,000−$17,000
Research and development$45.4m$29.9m$24.8m$8.9m$7.4m$3.7m
Operating income−$84.2m−$40.0m−$31.7m−$12.8m−$9.8m−$5.7m
Net income−$77.6m−$36.1m−$31.6m−$12.6m−$9.7m−$5.8m
Diluted earnings per share-2.31-1.15-1.12-0.61-1.01-0.65

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$780.6m$152.1m$94.6m$44.3m$18.3m$25.7m
Cash and short-term investments$492.4m$145.1m$88.2m$42.1m$17.3m$25.6m
Total liabilities$10.1m$6.3m$4.2m$2.8m$33.4m$32.8m
Debt$241,000$276,000$616,000$396,000——
Shareholders' equity$770.5m$145.8m$90.4m$41.5m−$15.1m−$7.0m
Shares outstanding34m31m28m21m10m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$37.0m−$29.2m−$29.8m−$11.5m−$7.5m−$4.4m
Capital spending−$178,000−$151,000−$63,000−$394,000−$74,000−$20,000
Free cash flow−$37.2m−$29.4m−$29.9m−$11.9m−$7.5m−$4.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$34.9m−$32.7m−$28.1m−$23.0m−$17.6m−$15.5m−$11.5m−$9.7m
Net income−$28.4m−$26.9m−$25.3m−$21.7m−$16.3m−$14.3m−$10.1m−$8.7m
Diluted earnings per share-0.71-0.67-0.76-0.65-0.49-0.43-0.32-0.28
Cash from operations——————−$4.0m—
Total assets—$811.3m$780.6m$282.4m$156.4m$164.2m$152.1m$115.8m
Cash and short-term investments——$492.4m$275.6m$149.2m$157.4m$145.1m$109.0m
Debt——$241,000$265,000——$276,000—
Shareholders' equity—$795.8m$770.5m$274.1m$149.9m$158.1m$145.8m$112.2m

Financial ratios

Data as of 14 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Return on equity-10.1%-24.8%-35.0%-30.5%64.0%81.8%
Return on assets-9.9%-23.8%-33.4%-28.6%-52.7%-22.3%
Free cash flow yield-0.7%-0.6%-0.7%-0.4%-0.5%-0.3%
Earnings growth114.7%14.3%150.1%30.9%68.0%—
Current ratio50.02x24.31x24.76x20.35x10.66x26.41x
Debt to equity0.00x0.00x0.00x0.00x——
Equity ratio98.7%95.9%95.6%93.7%-82.3%-27.3%
Interest coverage-38805.50x-1805.90x-1263.92x-789.50x-1933.20x-273.48x
Buybacks as a share of market value-6.6%-11.1%-37.1%-115.7%-8.2%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income87.3%71.1%—
Net income83.1%68.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-69.1-54.9-41.0-49.2

Market value over time

29 Apr 2022 to 13 Oct 2026, in USD

$255.2m$6.10bn

Share price return

Finished calendar years

2025202420232022
Return145%40%52%180%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.